Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL3621021 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL3544878 | 0.88 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1HPGDHSD17B10POLB | |
| SCHEMBL3544875 | 0.88 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1HPGDHSD17B10POLB | |
| SCHEMBL3547351 | 0.86 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL3547353 | 0.86 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1HPGDHSD17B10SMN1; SMN2 | |
| Hydroxyamine SCHEMBL5268858 | 0.79 | PDE4B (0.39) | ALDH1A1L3MBTL1LMNA | |
| Hydroxyamine SCHEMBL5268861 | 0.79 | PDE4B (0.39) | ALDH1A1L3MBTL1LMNA | |
| Hydroxyamine SCHEMBL5274854 | 0.76 | GAA (0.53) | ALDH1A1L3MBTL1POLB | |
| Hydroxyamine SCHEMBL5274861 | 0.76 | GAA (0.53) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL15595714 | 0.75 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1GYS1NPSR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | ALDH1A1 2309/4885L3MBTL1 1577/4885HPGD 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.